Federal workers get overdose kits; private employers just get a suggestion
S. 3812 — WORK to Save Lives Act · Filed by Jeff Merkley (D-OR) · 5 cosponsors · Introduced Feb 10, 2026 · Hearing held
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Department of Labor to issue non-binding guidance to private employers on acquiring opioid overdose reversal medication (like naloxone) and training employees to use it, and to issue binding regulations requiring all federal agencies to do the same within 270 days. Private employers are encouraged but not required; federal agencies must comply.
Why we flagged it
The bill's operative mechanism is a straightforward public-health mandate: requiring federal agencies and encouraging private employers to stock and train on overdose reversal medication. This is a workplace safety measure aimed at reducing opioid-related deaths.
What the text implies
- Federal agencies must bear the cost of acquiring and maintaining naloxone/overdose reversal medication indefinitely, with no appropriation specified — implementation cost falls on agency budgets.
- Annual training requirement for all federal employees may create administrative burden and compliance tracking obligations across thousands of agencies.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers of naloxone and overdose reversal medications; workplace safety training providers and consultants; occupational health and safety equipment suppliers